1
|
Kim SM, Rhee W, Ha S, Lim JH, Jang IT. Influence of alendronate and endplate degeneration to single level posterior lumbar spinal interbody fusion. KOREAN JOURNAL OF SPINE 2014; 11:221-6. [PMID: 25620981 PMCID: PMC4303280 DOI: 10.14245/kjs.2014.11.4.221] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/23/2014] [Revised: 11/21/2014] [Accepted: 11/24/2014] [Indexed: 11/19/2022]
Abstract
OBJECTIVE Using alendronate after spinal fusion is a controversial issue due to the inhibition of osteoclast mediated bone resorption. In addition, there are an increasing number of reports that the endplate degeneration influences the lumbar spinal fusion. The object of this retrospective controlled study was to evaluate how the endplate degeneration and the bisphosphonate medication influence the spinal fusion through radiographic evaluation. METHODS In this study, 44 patients who underwent single-level posterior lumbar interbody fusion (PLIF) using cage were examined from April 2007 to March 2009. All patients had been diagnosed as osteoporosis and would be recommended for alendronate medication. Endplate degeneration is categorized by the Modic changes. The solid fusion is defined if there was bridging bone between the vertebral bodies, either within or external to the cage on the plain X-ray and if there is less than 5° of angular difference in dynamic X-ray. RESULTS In alendronate group, fusion was achieved in 66.7% compared to 73.9% in control group (no medication). Alendronate did not influence the fusion rate of PLIF. However, there was the statistical difference of fusion rate between the endplate degeneration group and the group without endplate degeneration. A total of 52.4% of fusion rate was seen in the endplate degeneration group compared to 91.3% in the group without endplate degeneration. The endplate degeneration suppresses the fusion process of PLIF. CONCLUSION Alendronate does not influence the fusion process in osteoporotic patients. The endplate degeneration decreases the fusion rate.
Collapse
Affiliation(s)
- Sang-Mok Kim
- Department of Neurosurgery, Seoul Nanoori Hospital, Seoul, Korea
| | - Wootack Rhee
- Department of Neurosurgery, Seoul Nanoori Hospital, Seoul, Korea
| | - Seongil Ha
- Department of Neurosurgery, Seoul Nanoori Hospital, Seoul, Korea
| | - Jae Hyeon Lim
- Department of Neurosurgery, Seoul Nanoori Hospital, Seoul, Korea
| | - Il Tae Jang
- Department of Neurosurgery, Seoul Nanoori Hospital, Seoul, Korea
| |
Collapse
|
2
|
|
3
|
Cardona Tortajada F, Sainz Gómez E, Figuerido Garmendia J, Lirón de Robles Adsuar A. [Chronic mouth ulcer due to inadequate ingestion of alendronate]. Aten Primaria 2009; 40:430-1. [PMID: 18755110 DOI: 10.1157/13125415] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
|
4
|
Er K, Polat ZA, Özan F, Taşdemir T, Sezer U, Siso ŞH. Cytotoxicity Analysis of Strontium Ranelate on Cultured Human Periodontal Ligament Fibroblasts: A Preliminary Report. J Formos Med Assoc 2008; 107:609-15. [DOI: 10.1016/s0929-6646(08)60178-3] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
5
|
Lustosa-Pereira A, Garcia RB, de Moraes IG, Bernardineli N, Bramante CM, Bortoluzzi EA. Evaluation of the topical effect of alendronate on the root surface of extracted and replanted teeth. Microscopic analysis on rats' teeth. Dent Traumatol 2006; 22:30-5. [PMID: 16422756 DOI: 10.1111/j.1600-9657.2006.00417.x] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
The treatment of choice for tooth avulsion is replantation. The ideal replantation should be realized as quickly as possible, or at least, the avulsed tooth should be kept in an adequate solution to preserve the periodontal ligament attached to the root. If that is not possible, treatment of the radicular surface should be done in order to prevent radicular resorption. The purpose of this study was to test sodium alendronate as a substance for topical treatment of the radicular surface of avulsed teeth in an attempt to prevent the occurrence of dental resorptions. Fifty-four rat maxillary right central incisors were extracted and replanted. Group I--extra-alveolar dry period of 15 min, intracanal dressing with calcium hydroxide (CALEN, S.S. White, Artigos Dentários LTDA, Rio de Janeiro, Brazil) and replantation; Groups II and III - extra-alveolar dry periods of 30 and 60 min, respectively, immersion in 1% sodium hypochlorite for 30 min for removal of the periodontal ligament, washing in saline solution for 5 min, and treatment of the radicular surface with 3.2 mg/l sodium alendronate solution for 10 min. Intracanal dressing with calcium hydroxide and replantation followed. At 15, 60, and 90 days post-reimplantation, the animals were killed and the samples obtained and processed for microscopic analysis. The results indicated that sodium alendronate was able to reduce the incidence of radicular resorption, but not of dental ankylosis. No significant differences were observed regarding variations in the extra-alveolar periods among the groups.
Collapse
Affiliation(s)
- Adriana Lustosa-Pereira
- Department of Endodontics, Bauru Dental School, University of São Paulo, Bauru, São Paulo, Brazil.
| | | | | | | | | | | |
Collapse
|
6
|
Kum KY, Park JH, Yoo YJ, Choi BK, Lee HJ, Lee SJ. The inhibitory effect of alendronate and taurine on osteoclast differentiation mediated by Porphyromonas gingivalis sonicates in vitro. J Endod 2003; 29:28-30. [PMID: 12540215 DOI: 10.1097/00004770-200301000-00008] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
The objective of this study was to investigate the ability of alendronate and taurine in inhibiting in vitro osteoclast differentiation induced by bacteria. Whole cell sonicates of Porphyromonas gingivalis were used as an osteoclast-stimulating factor in a mouse coculture system and differentiated osteoclasts were confirmed by tartrate-resistant acid phosphatase (TRAP) staining. Alendronate at the concentrations of 10(-7) M, 10(-6) M, and 10(-5) M and taurine at the concentrations of 4 mM, 8 mM, and 12 mM were used. The cytotoxic effects of alendronate and taurine were examined using methylthiazole-tetrazolium bromide (MTT) assay. The amounts of interleukin-6 (IL-6) in culture supernatants were also measured using ELISA. The sonicates of P. gingivalis at the concentration of 0.01-0.1 microg/ml significantly stimulated the formation of osteoclasts (p < 0.05). Alendronate (10(-5) M) and taurine (12 mM) significantly suppressed the sonicate-stimulated osteoclast formation. In MTT assay, no cytotoxic effects were evident in all concentrations of alendronate and taurine. Alendronate and taurine did not affect the amount of IL-6 induced by P. gingivalis sonicates. These data indicate that alendronate and taurine have inhibitory effects on bacteria-stimulated osteoclast formation in vitro and that this inhibitory mechanism is not related to the blocking of IL-6 production.
Collapse
Affiliation(s)
- Kee-Yeon Kum
- Department of Conservative Dentistry, College of Dentistry, Yonsei University, Seoul, Korea
| | | | | | | | | | | |
Collapse
|
7
|
Posaci C, Altunyurt S, Islekel H, Saygili U, Altekin E, Onvural A, Onvural B. The values of urinary NTx in postmenopausal women undergoing HRT; the role of additional alendronate therapy. Maturitas 2002; 42:281-6. [PMID: 12191850 DOI: 10.1016/s0378-5122(02)00156-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
OBJECTIVE To determine the changes in levels of urinary NTx at the end of the 6th month of oral and transdermal hormone replacement therapy (HRT) and the effects of additional alendronate therapy for osteoporotic women. METHOD Of 66 postmenopausal women 23 were treated with oral estradiol+norethisterone acetate (E+P), and 22 were treated with transdermal estradiol+norethisterone acetate. The third group consisted of 21 women with osteoporosis (bone mineral density < 100 mg/cm(3)) and treated with oral E+P plus alendronate 10 mg/day. RESULT Significant decreases of urinary NTx levels were seen after HRT in all study groups (P < 0.05). But the decline of NTx levels was not different between the oral and transdermal HRT groups (P > 0.05). There was no additional decrease in the levels of NTx with alendronate therapy (P > 0.05) but NTx excretion diminished more in patients with high baseline levels. CONCLUSION The decline of NTx at the end of the 6th month of HRT reflects the decrease of bone resorption and it is not related to the route of administration.
Collapse
Affiliation(s)
- Cemal Posaci
- Department of Obstetrics and Gynecology, Dokuz Eylul University, Faculty of Medicine, 35340 Inciralti, Izmir, Turkey
| | | | | | | | | | | | | |
Collapse
|
8
|
Iwaniec UT, Samnegård E, Cullen DM, Kimmel DB. Maintenance of cancellous bone in ovariectomized, human parathyroid hormone [hPTH(1-84)]-treated rats by estrogen, risedronate, or reduced hPTH. Bone 2001; 29:352-60. [PMID: 11595618 DOI: 10.1016/s8756-3282(01)00582-8] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
This study compares effects of maintenance doses of human parathyroid hormone [hPTH(1-84)], 17beta-estradiol (E2), and risedronate on distal femur bone mineral density and proximal tibia cancellous bone histomorphometry in ovariectomized (ovx), osteopenic rats previously administered a higher dose of hPTH. Nine groups (n = 8) of 3.5-month-old ovx or intact Sprague-Dawley rats were left untreated for 11 weeks to allow for the development of cancellous osteopenia in the ovx groups. Next, the ovx rats received subcutaneous injections of hPTH (75 microg/kg per day, three times per week) or vehicle for 12 weeks. Treatments were then changed to E2 (10 microg/kg per day, two times per week), risedronate (Ris; 3 microg/kg per day, three times per week), low-dose hPTH(1-84) (LowPTH; 25 microg/kg per day, three times per week), or vehicle, and administered for 36 weeks. The intact control group remained untreated for the duration of study. Femora and tibiae were collected at weeks -11 (baseline); 0 (ovx effect); 12 (hPTH effect), and 24, 36, and 48 (maintenance effects). Endpoints evaluated included distal femur bone mineral density (BMD) and proximal tibia cancellous bone volume (BV/TV), osteoclast surface (Oc.S), mineralizing surface (MS), mineral apposition rate (MAR), and bone formation rate (BFR). Ovariectomy had a negative effect on distal femur BMD and proximal tibia BV/TV. Treatment of ovx rats with hPTH for 12 weeks resulted in higher BMD in comparison to intact controls, and higher cancellous BV/TV in comparison to ovx controls. Discontinuation of hPTH resulted in loss of gained BMD within 24 weeks and loss of gained BV/TV within 12 weeks. Treatment of ovx rats with hPTH for 12 weeks followed by E2 treatment left BMD and BV/TV similar to vehicle-treated ovx rats by week 48 (36 weeks after commencement of the E2 maintenance treatment). Maintenance treatment with risedronate resulted in BMD and BV/TV similar to that of intact controls. Maintenance treatment with low-dose hPTH resulted in greater BMD and similar BV/TV in comparison to intact controls. MS and BFR were highest after low-dose hPTH administration. MS and BFR were lowest after E2 or risedronate, whereas Oc.S was lowest after risedronate administration. Thus, in osteopenic rats, the increment in distal femur BMD and proximal tibia BV/TV gained by 12 weeks of hPTH treatment was lost within 24 and 12 weeks of treatment termination, respectively. Low-dose hPTH maintained BMD and BV/TV after hPTH treatment by stimulating bone formation, whereas risedronate maintained BMD and BV/TV by reducing bone resorption. E2 in a maintenance dose failed to maintain BMD and BV/TV after withdrawal of hPTH treatment.
Collapse
Affiliation(s)
- U T Iwaniec
- Osteoporosis Research Center, Creighton University, Omaha, NE, USA.
| | | | | | | |
Collapse
|
9
|
Abstract
In postmenopausal women tibolone has proved to prevent bone-loss and relieve climacteric symptoms as effectively as estrogens, but it does not stimulate the endometrium and the breast. This clinical profile strongly suggests that tibolone is a compound with tissue-specific action. Tibolone is quickly metabolized into its main active metabolites, 3alpha and 3beta-OH, which are also present in an inactive, sulphated, form. In addition a Delta4-metabolite is found in circulation. The 3-OH-metabolites bind only to the estrogen receptor while the Delta4-isomer shows affinity only to the progesterone and androgen receptors. Tibolone prevents bone loss in a similar way to estrogens. Studies on bone mass using anti-estrogen, antiprogestin and anti-androgen in combination with tibolone, confirmed the sole involvement of the estradiol receptor. Increases in skin temperature as well as vaginal atrophy can be prevented by tibolone in a similar way to estrogens. Breast safety studies showed that tibolone clearly inhibited the growth of tumors in a DMBA model. In breast cell lines, tibolone profoundly inhibited sulphatase activity and an increase in apoptosis and decrease in cell proliferation was found. The stimulation of the endometrium is prevented by the local formation of the Delta4-isomer from tibolone or the 3beta-OH-metabolite. We conclude that tibolone acts as a tissue-specific compound by mediating its effects via steroid receptors and enzymatic pathways. This dual effect of tibolone explains it's positive clinical effects on bone, vagina and brain, and avoids stimulation of the endometrium and breast tissue.
Collapse
Affiliation(s)
- H J Kloosterboer
- NV Organon, Research and Development Laboratories, P.O. Box 20, 5340, Oss, The Netherlands.
| |
Collapse
|
10
|
Ezra A, Golomb G. Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv Drug Deliv Rev 2000; 42:175-95. [PMID: 10963835 DOI: 10.1016/s0169-409x(00)00061-2] [Citation(s) in RCA: 165] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Geminal bisphosphonates (BPs) are a class of drugs considered to be stable analogs of pyrophosphate (P-O-P), a physiological regulator of calcification and bone resorption. A number of BPs have been approved for clinical use in Paget's disease, hypercalcemia of malignancy, and osteoporosis. The major disadvantage of the clinically utilized BPs is their poor oral absorption from the GI tract, typically less than 1% is absorbed. In addition, the BPs have been associated with adverse gastrointestinal effects in humans. The challenge for novel drug delivery systems is to achieve improved bioavailability and safety. In the first part of this review, we discuss the bioavailability of BPs, the effect of food on the absorption of BPs, the mechanism of BPs' absorption and the adverse gastrointestinal effects. In the second part of the review, various methods that have been used for improving the bioavailability of BPs are described. Dosage form strategies reviewed include the use of particular formulations for increasing oral absorption as well as decreasing adverse gastrointestinal effects, absorption enhancers, BP compounds and the solubility of their calcium complex/salts, and the prodrug approach. Because of the poor GI absorption, attempts have been made to enhance the bioavailability of BPs by several parenteral routes other than i.v. injections. Description of nasal administration, s.c. and i.m. injections, BP implants and targeted osteotropic delivery systems are reviewed.
Collapse
Affiliation(s)
- A Ezra
- Department of Pharmaceutics, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, POB 12065, 91120, Jerusalem, Israel
| | | |
Collapse
|
11
|
Beauchesne MF, Miller PF. Etidronate and alendronate in the treatment of postmenopausal osteoporosis. Ann Pharmacother 1999; 33:587-99. [PMID: 10369624 DOI: 10.1345/aph.18212] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
OBJECTIVE To review the clinical trials evaluating the efficacy of etidronate and alendronate in the treatment of established postmenopausal osteoporosis. DATA SOURCE A MEDLINE search was performed (from 1966 through September 1998) using the search terms bisphosphonates, etidronate, alendronate, and postmenopausal osteoporosis. English-language articles were considered for review. STUDY SELECTION AND DATA EXTRACTION Prospective, randomized, double-blind, placebo-controlled clinical trials using fracture as an end point were selected to review the efficacy of etidronate and alendronate in the treatment of postmenopausal osteoporosis. Results for the outcomes of bone mineral density (BMD) and fracture are summarized. DATA SYNTHESIS Etidronate and alendronate increase spinal BMD in postmenopausal women with osteoporosis. In one study, etidronate decreased the number of women sustaining new radiographic vertebral fractures over two years, but this effect was lost after three years of treatment. Alendronate reduces the number of radiographic vertebral fractures in postmenopausal women with a low bone mass. In women with preexisting fractures, alendronate decreases the number of patients with radiographic vertebral fractures, clinical (i.e., symptomatic vertebral and nonvertebral) fractures, and hip fractures. A significant reduction in the overall number of nonvertebral fractures has not been demonstrated in clinical trials evaluating either alendronate or etidronate. CONCLUSIONS No studies have directly compared the efficacy of alendronate and etidronate and the results of long-term clinical trials (i.e., >5 y) have not been published. Based on the results obtained in clinical trials using fracture as an end point, alendronate appears to be the bisphosphonate of choice. Safety profiles and cost should also be considered in the choice of etidronate or alendronate for the treatment of postmenopausal osteoporosis.
Collapse
Affiliation(s)
- M F Beauchesne
- Pharmacy Department, Sacré-Coeur Hospital, Montréal, Québec, Canada
| | | |
Collapse
|
12
|
|
13
|
Abstract
Dual-energy x-ray absorptiometry (DXA) is widely used for identifying patients with osteoporosis, making decisions about the commencement of preventive therapy, and following up response to treatment. It is important that radiologists and nuclear medicine physicians issuing clinical reports present clear interpretations that aid the primary care physician in making decisions affecting treatment. This review discusses the principles behind the interpretation of bone mineral density (BMD) studies. After a World Health Organization report published in 1994, osteoporosis is often diagnosed on the basis of the patient's T-score value (difference of BMD from young adult mean normalized to the population SD). T-scores are a measure of current fracture risk. There are problems relating to the use of T-scores in the elderly, and we argue that decisions about treatment are generally best made on the basis of the Z-score value (difference of BMD from age-matched mean normalized to the population SD) because this measures the patient's fracture risk relative to his or her peers. Recent studies confirm that the posteroanterior (PA) projection lumbar spine scan is still the optimum measurement site for monitoring response to treatment. A BMD change of 4.5% is required to register a statistically significant change.
Collapse
Affiliation(s)
- G M Blake
- Department of Nuclear Medicine, Guy's Hospital, London, United Kingdom
| | | |
Collapse
|